In December 2009, well known U.S Venture Capital Fund, Bioveda and NEA successfully acquired and reconstructed Jiangxi Lixin Pharmaceutical Co. Ltd.. Bioveda China Fund is a first venture capital in the global market only focused on China Bio and Pharmaceutical sectors, discovering and investing in those rapid growing companies which have both an advanced technology and an outstanding management team. Bioveda and NEA provide great financial and strategic support to Jiangxi Lixin Pharmaceutical Co for further more development.
Our main products are Meropenem intermediates including 4BMA,F9, MAP/MVP which are the intermediates of biapenem and Etapenem too, Meropenem Sterile API, Meropenem for injection, Meropenem formulation and Fenofibrate acid. Our company is committed to continuous improvement and consolidation of the traditional products, and concurrently developing new products. The company has provincial level technical research center, equipped with advanced devices and equipments, and staffed with a number of Masters and Doctors in the R&D team.
Our company is in the process of planning a new plant covering 70 acres, a predicted investment over $200 million US to build new manufacturer plant to produce a new product (Edinafi). This project is highly valued and fully supported both by the local and the provincial government. It has great market potential and will be competitive. This new facility will also increase the production capacity of Meropenem sterile API and Formulations and other Anti-biotic and anti-virus API and Intermediates. It is expected to complete in 2014 and sales amount will achieve $500 million US.
Our company always follow its own beliefs of building trust from customers, returning to the community, and continuously improving our service to all customers both from domestic and abroad.
